Literature DB >> 6274087

Revertants of rats cells transformed by avian erythroblastosis virus.

K Quade1, S Saule, D Stéhelin, G Kitchener, M J Hayman.   

Abstract

Morphological revertants of the avian erythroblastosis virus (AEV)-transformed rat cell line ATla were isolated and characterised. The revertants are similar to the uninfected parental rat cell line in that they have regained an organized cytoskeleton and they are no longer capable of anchorage-independent growth. The pattern of integrated viral DNA in the revertants is indistinguishable from that of the transformed parent. However, the revertants do not express the integrated viral genome at either the mRNA or protein level. Phenotypic reversion thus is probably .due to reduced transcription of the AEV-transforming gene below a threshold necessary to induce morphological transformation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6274087     DOI: 10.1016/0042-6822(81)90114-8

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  4 in total

1.  DNA methylation and transcriptional controls of proviral DNA in avian sarcoma virus-transformed mammalian cells.

Authors:  F Catala
Journal:  Nucleic Acids Res       Date:  1986-03-25       Impact factor: 16.971

2.  Sensitization of transformed rat fibroblasts to killing by parvovirus minute virus of mice correlates with an increase in viral gene expression.

Authors:  J J Cornelis; N Spruyt; P Spegelaere; E Guetta; T Darawshi; S F Cotmore; J Tal; J Rommelaere
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

3.  Revertants and partial transformants of rat fibroblasts infected with Fujinami sarcoma virus.

Authors:  B Mathey-Prevot; M Shibuya; J Samarut; H Hanafusa
Journal:  J Virol       Date:  1984-05       Impact factor: 5.103

4.  Effects of inhibitors of glycoprotein processing on the synthesis and biological activity of the erb B oncogene.

Authors:  J A Schmidt; H Beug; M J Hayman
Journal:  EMBO J       Date:  1985-01       Impact factor: 11.598

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.